News

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 ...
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of ...
Avalo Therapeutics: Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of appro ...
Healio10d
Topline data show upadacitinib improved severe alopecia
AbbVie released positive topline data from its phase 3 UP-AA trial demonstrating safety and efficacy for upadacitinib for ...
The Malaysian Reserve11d
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...